New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Patients who fasted during chemotherapy for ovarian cancer had significantly longer progression-free survival (PFS) compared ...

New Delhi | A Delhi hospital has performed a complex hip reconstruction surgery using a patient-specific 3D-printed implant on a 28-year-old man suffering from chronic infection and severe bone loss ...

Researchers at Lund University have validated a blood-based method for measuring circulating tumor DNA in patients with early ...

LAHORE: Nishtar Hospital administration on Friday suspended from service 10 doctors, including senior registrar (surgery), ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...

The ward in-charge claimed that the operating theatre and all surgical instruments were cleaned early on Wednesday morning.

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...

Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial. Two new indications bring Daiichi Sankyo and ...